miR-545 inhibited pancreatic ductal adenocarcinoma growth by targeting RIG-I

被引：49

作者：

Song, Bin ^{[1
]}

Ji, Weiping ^{[1
]}

Gu, Shiwei ^{[1
]}

Liu, Anan ^{[1
]}

Jing, Wei ^{[1
]}

Shao, Chenghao ^{[1
]}

Li, Gang ^{[1
]}

Jin, Gang ^{[1
]}

机构：

[1] Second Mil Med Univ, Dept Pancreat Surg, Changhai Hosp, Shanghai 200082, Peoples R China

来源：

FEBS LETTERS | 2014年 / 588卷 / 23期

基金：

上海市自然科学基金;

关键词：

miR-545; Pancreatic ductal adenocarcinoma; RIG-I; Patients survival; Cancer growth; HEPATOCELLULAR-CARCINOMA; MICRORNAS; CANCER; RECOGNITION; SURVIVAL; RNA; ACTIVATION; APOPTOSIS; GENES; CELLS;

D O I：

10.1016/j.febslet.2014.10.004

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Pancreatic ductal adenocarcinoma (PDAC) ranks fourth on the list of cancer-related causes of death. Deregulation or dysfunction of miRNAs contribute to cancer development. In this study, we found that low miR-545 level and high RIG-I protein in PDAC tissues were both correlated with low survival rate. MiR-545 up-regulation inhibited PDAC cell lines growth and vice versa. 3'UTR of RIG-I was targeted by miR-545. Thus we concluded that low miR-545 levels in PDAC promote tumor cells growth, and this is associated with reduced survival in PDAC patients. MiR-545 exerts its effects by directly targeting RIG-1. (C) 2014 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.

引用

页码：4375 / 4381

页数：7

共 50 条

[41] MiR-143-3p suppresses tumorigenesis in pancreatic ductal adenocarcinoma by targeting KRAS
Xie, Fei
Li, Chuan
Zhang, Xiaoyun
Peng, Wei
Wen, Tianfu
BIOMEDICINE & PHARMACOTHERAPY, 2019, 119
[42] Targeting the prohibitin scaffold-CRAF kinase interaction in RAS-ERK-driven pancreatic ductal adenocarcinoma
Luan, Zhou
He, Ying
Alattar, Mohamed
Chen, Zhishui
He, Fan
MOLECULAR CANCER, 2014, 13
[43] Vasohibin-2-Targeting Therapies for the Treatment of Pancreatic Ductal Adenocarcinoma
Suzuki, Yasuhiro
Sato, Yasufumi
TOHOKU JOURNAL OF EXPERIMENTAL MEDICINE, 2024, 262 (03) : 163 - 171
[44] Adrenomedullin promotes the growth of pancreatic ductal adenocarcinoma through recruitment of myelomonocytic cells
Xu, Min
Qi, Feifei
Zhang, Shaosen
Ma, Xuhui
Wang, Shan
Wang, Chunying
Fu, Yan
Luo, Yongzhang
ONCOTARGET, 2016, 7 (34) : 55043 - 55056
[45] PNMA1 promotes cell growth in human pancreatic ductal adenocarcinoma
Jiang, Shu-Heng
He, Ping
Ma, Ming-Ze
Wang, Yang
Li, Rong-kun
Fang, Fang
Fu, Ying
Tian, Guang-Ang
Qin, Wen-Xin
Zhang, Zhi-Gang
INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY, 2014, 7 (07): : 3827 - 3835
[46] miR-124 Suppresses Pancreatic Ductal Adenocarcinoma Growth by Regulating Monocarboxylate Transporter 1-Mediated Cancer Lactate Metabolism
Wu, De-Hai
Liang, Hao
Lu, Shou-Nan
Wang, Hao
Su, Zhi-Lei
Zhang, Lei
Ma, Jian-Qun
Guo, Mian
Tai, Sheng
Yu, Shan
CELLULAR PHYSIOLOGY AND BIOCHEMISTRY, 2018, 50 (03) : 924 - 935
[47] Concurrent targeting of GSK3 and MEK as a therapeutic strategy to treat pancreatic ductal adenocarcinoma
Fukuda, Junki
Kosuge, Shinya
Satoh, Yusuke
Sekiya, Sho
Yamamura, Ryodai
Ooshio, Takako
Hirata, Taiga
Sato, Reo
Hatanaka, Kanako C.
Mitsuhashi, Tomoko
Nakamura, Toru
Matsuno, Yoshihiro
Hatanaka, Yutaka
Hirano, Satoshi
Sonoshita, Masahiro
CANCER SCIENCE, 2024, 115 (04) : 1333 - 1345
[48] Selective RNA targeting and regulated signaling by RIG-I is controlled by coordination of RNA and ATP binding
Fitzgerald, Megan E.
Rawling, David C.
Potapova, Olga
Ren, Xiaoming
Kohlway, Andrew
Pyle, Anna Marie
NUCLEIC ACIDS RESEARCH, 2017, 45 (03) : 1442 - 1454
[49] Nanoparticle Delivery of RIG-I Agonist Enables Effective and Safe Adjuvant Therapy in Pancreatic Cancer
Das, Manisit
Shen, Limei
Liu, Qi
Goodwin, Tyler J.
Huang, Leaf
MOLECULAR THERAPY, 2019, 27 (03) : 507 - 517
[50] The miR-217 microRNA functions as a potential tumor suppressor in pancreatic ductal adenocarcinoma by targeting KRAS
Zhao, Wu-Gan
Yu, Shuang-Ni
Lu, Zhao-Hui
Ma, Yi-Hui
Gu, Yu-Mei
Chen, Jie
CARCINOGENESIS, 2010, 31 (10) : 1726 - 1733

← 1 2 3 4 5 →